Markus M. Borner, MD

home / authors / markus-m-borner-md

Articles

Management of Infusion Reactions in Clinical Trials and Beyond: The US and EU Perspectives

Anthony J. Cmelak, MD;Florian Lordick, MD;Markus M. Borner, MD;Richard M. Goldberg, MD;Muhammad Wasif Saif, MD

February 2nd 2009

Infusion reactions (IRs) can be broadly categorized by their immunologic mechanism. Anaphylaxis is a systemic, immediate hypersensitivity reaction mediated by factors released from interactions between immunoglobulin E (IgE) and mast cells that produce an antigen-antibody reaction.[1] Anaphylactoid reactions can be differentiated from anaphlaxis by the fact that they are not IgE-mediated but rather cytokine-mediated.

Commentary (Markus/Studer)-Testicular Cancer: What’s New in Staging, Prognosis, and Therapy

Markus M. Borner, MD;Urs E. Studer, MD

December 1st 1999

The management of patients with clinical stage I nonseminomatous germ-cell tumors is still highly controversial. In a recent survey, urologists and oncologists were asked to state their choice of treatment for patients with clinical stage I nonseminomas who were at high risk for recurrence after orchiectomy. Not surprisingly, urologists chose retroperitoneal lymph node dissection over chemotherapy, while oncologists indicated a preference for adjuvant chemotherapy.[1]

UFT and Oral Calcium Folinate as First-Line Chemotherapy for Metastatic Gastric Cancer

Alain Ravaud, MD, PhD;Markus M. Borner, MD;Jan H. M. Schellens, MD;Lionnel Geoffrois, MD;Patrick Schöffski, MD;Jantien Wanders, MD;Axel R. Hanauske, MD, PhD

July 1st 1999

Locally advanced or metastatic adenocarcinoma of the stomach still carries a poor prognosis, with 5-year survival rates of < 15%. Palliative chemotherapeutic regimens for this disease are largely 5-FU–based. We